Hemodialysis Catheter Market: as CorMedix's DefenCath keeps compounding revenue quarter after quarter on the strength of a single antimicrobial catheter lock solution, the company's August 2025 acquisition of an entire infectious-disease drug portfolio signals it is building toward a broader catheter-adjacent infection-prevention business rather than defending one product indefinitely, so the competitive question for established catheter makers is no longer whether antimicrobial lock technology matters but which company will own the surrounding infection-prevention ecosystem that catheter purchasing decisions increasingly depend on.

The global hemodialysis catheter market size was USD 1.06 Billion in 2025 and is expected to register a revenue CAGR of 6.8% during the forecast period. Market revenue growth is driven by factors such as sustained growth in the chronic kidney disease patient population requiring vascular access, antimicrobial catheter lock solution adoption reducing catheter-related bloodstream infection rates, and established manufacturers extending combined catheter-and-infection-prevention commercial platforms. The first driving factor is sustained growth in the chronic kidney disease patient population, which continues to expand the base of patients requiring either tunneled or non-tunneled catheter-based dialysis access. Tunneled hemodialysis catheters account for approximately 53% of total 2025 market revenue, reflecting the clinical preference for tunneled access in patients requiring longer-term dialysis. The second driving factor is antimicrobial catheter lock solution adoption, which addresses catheter-related bloodstream infection, one of the most significant complications associated with catheter-based dialysis access. The third driving factor is established manufacturers extending combined catheter-and-infection-prevention commercial platforms that bundle hardware with complementary pharmaceutical or antimicrobial products. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single antimicrobial catheter lock solution's clinical and commercial success creates room for its developer to expand into an adjacent infection-prevention product portfolio, which converts one successful drug-device combination product into a broader platform addressing catheter-related infection risk from multiple angles. Because a catheter-related bloodstream infection prevention product's commercial success depends on the same outpatient dialysis provider relationships that a broader infectious disease portfolio would also serve, a company that has already built deep commercial relationships with the largest dialysis organizations through one successful product is well positioned to introduce additional complementary infection-prevention products through those same relationships. As a result, demand and revenue share in the antimicrobial catheter lock category are concentrating around companies building a broader infection-prevention commercial platform, and the forecast tilts toward manufacturers who can bundle catheter hardware with complementary pharmaceutical products rather than hardware-only vendors. For instance, in August 2025, CorMedix acquired Melinta Therapeutics, an infectious disease-focused pharmaceutical portfolio, extending the company's commercial reach beyond its DefenCath antimicrobial catheter lock solution into a broader infection-prevention and treatment business built on the same outpatient dialysis provider relationships. These are some of the key factors driving revenue growth of the market.

Because catheter-related bloodstream infection remains a documented risk even with antimicrobial lock solution use, though at meaningfully reduced rates, hospitals and dialysis centres continue to invest in infection prevention protocols beyond the catheter and lock solution alone, adding cost and complexity to catheter-based vascular access programmes.

Central venous stenosis risk is a second constraint, because long-term catheter use is associated with a documented risk of central vein narrowing that can complicate future vascular access options, which is why clinical guidelines generally favor arteriovenous fistula or graft access over catheter-based access wherever clinically feasible for chronic dialysis patients.

Reimbursement variability for antimicrobial lock solutions is a third constraint, since coverage and reimbursement transition mechanisms for newer antimicrobial catheter lock products vary by payer and are subject to policy changes as temporary add-on payment mechanisms phase into standard reimbursement structures.

These factors substantially limit hemodialysis catheter market growth over the forecast period.

The clearest driver of demand is sustained growth in the chronic kidney disease patient population, which continues to expand the base of patients requiring either tunneled or non-tunneled catheter-based dialysis access. Not every dialysis patient is a candidate for arteriovenous fistula or graft access, particularly those with limited vasculature or those requiring urgent dialysis initiation, so catheter-based access remains a clinically necessary option for a meaningful share of the growing chronic kidney disease population regardless of guideline preference for fistula access where feasible. Tunneled hemodialysis catheters account for approximately 53% of total 2025 market revenue, and BD reported holding more than 13.9% global market share in the hemodialysis catheter category in 2024 through its Power-Trialysis and Arrowg+ard portfolio. The effect on the market is that baseline catheter demand grows with the chronic kidney disease patient population, providing a demand floor independent of any single manufacturer's product innovation cycle. These are some of the key factors driving revenue growth of the market.

The second driver is antimicrobial catheter lock solution adoption, which directly addresses catheter-related bloodstream infection, a serious and costly complication of catheter-based dialysis access. A catheter lock solution that reduces bloodstream infection risk addresses both a direct patient safety concern and a significant cost driver for dialysis providers, since treating a catheter-related bloodstream infection typically requires hospitalisation and antibiotic therapy that a prevention-focused lock solution can help avoid. CorMedix's DefenCath, the first and only FDA-approved antimicrobial catheter lock solution for catheter-related bloodstream infection reduction in chronic hemodialysis patients, has continued to expand utilisation among outpatient dialysis organizations, with the company reporting sustained quarter-over-quarter revenue growth through 2025. The effect on the market is that antimicrobial lock solution revenue is becoming a distinct and rapidly growing category within the broader hemodialysis catheter market, separate from catheter hardware revenue itself. These are some of the key factors driving revenue growth of the market.

CorMedix's DefenCath has driven the company toward a full-year 2025 pro forma revenue run rate exceeding USD 400 million. A single antimicrobial catheter lock solution has become significant enough to fund an entire infectious-disease portfolio acquisition.

The third driver is the extension of combined catheter-and-infection-prevention commercial platforms, as manufacturers bundle catheter hardware with complementary pharmaceutical or antimicrobial products sold through the same dialysis provider relationships. A dialysis provider's purchasing relationship for catheter hardware and its purchasing relationship for infection-prevention pharmaceutical products increasingly overlap with the same clinical and procurement stakeholders, so a company that can offer both through one commercial relationship reduces the provider's vendor management burden while capturing a larger share of the provider's total vascular access spend. In August 2025, CorMedix acquired Melinta Therapeutics, an infectious disease-focused pharmaceutical portfolio, extending its commercial reach beyond DefenCath into a broader infection-prevention and treatment business built on the same outpatient dialysis provider relationships that DefenCath established. The effect on the market is that competitive positioning in the antimicrobial lock and infection-prevention adjacent category increasingly depends on portfolio breadth and provider relationship depth, not a single product's clinical merits alone. These are some of the key factors driving revenue growth of the market.

However, the hemodialysis catheter market faces severe adoption constraints from catheter-related bloodstream infection risk that persists despite antimicrobial lock solutions and central venous stenosis risk associated with long-term catheter use.

Because catheter-related bloodstream infection remains a documented risk even with antimicrobial lock solution use, though at meaningfully reduced rates, hospitals and dialysis centres continue to invest in infection prevention protocols beyond the catheter and lock solution alone, adding cost and complexity to catheter-based vascular access programmes.

Central venous stenosis risk compounds this, because long-term catheter use is associated with a documented risk of central vein narrowing that can complicate future vascular access options, which is why clinical guidelines generally favor arteriovenous fistula or graft access over catheter-based access wherever clinically feasible for chronic dialysis patients.

Reimbursement variability for antimicrobial lock solutions is the third constraint, since coverage and reimbursement transition mechanisms for newer antimicrobial catheter lock products vary by payer and are subject to policy changes as temporary add-on payment mechanisms phase into standard reimbursement structures, which can affect near-term utilisation growth independent of clinical demand.

These factors substantially limit hemodialysis catheter market growth over the forecast period.

Based on product, the global hemodialysis catheter market is segmented into tunneled and non-tunneled hemodialysis catheters. Tunneled hemodialysis catheters hold the largest revenue share, because they are the clinically preferred option for patients requiring longer-term catheter-based dialysis access, which suits a market where chronic dialysis patient volume outweighs acute, short-term catheter placements. Non-tunneled hemodialysis catheters remain established for acute kidney injury and urgent dialysis initiation and are typically lower-cost given their shorter intended use duration. Non-tunneled catheters are expected to register the fastest revenue growth rate in the global hemodialysis catheter market over the forecast period, driven by rising acute kidney injury incidence in hospitalised patients requiring urgent temporary dialysis access.

Based on design, the global hemodialysis catheter market is segmented into double lumen, triple lumen, and split-tip catheter designs. Double lumen design holds the largest revenue share, because it remains the standard configuration for the majority of hemodialysis catheter placements, which ties directly back to the chronic dialysis demand described in the market's primary demand driver. Split-tip design is expected to register the fastest revenue growth rate in the global hemodialysis catheter market over the forecast period, driven by clinical evidence supporting improved blood flow rates and reduced recirculation with split-tip configurations relative to conventional co-axial designs.

Chronic kidney disease long-term dialysis application is expected to account for the largest revenue share in the global hemodialysis catheter market during the forecast period

Based on application, the global hemodialysis catheter market is segmented into chronic kidney disease long-term dialysis and acute kidney injury temporary dialysis access. Chronic kidney disease long-term dialysis holds the largest revenue share, reflecting the scale of the global chronic dialysis patient population relative to acute, temporary catheter placements. Acute kidney injury temporary dialysis access is expected to register the fastest revenue growth rate in the global hemodialysis catheter market over the forecast period, driven by rising acute kidney injury incidence in intensive care and hospitalised patient populations.

Based on regional analysis, the hemodialysis catheter market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of outpatient dialysis organizations and antimicrobial catheter lock solution adoption creates the deepest catheter-and-infection-prevention commercial market globally, and because BD, CorMedix, and Teleflex all maintain their primary commercial presence in the US market. CorMedix's expanding DefenCath utilisation among the largest US dialysis organizations specifically reinforces the region's position. The concentration of FDA clearance and approval activity in the country also means new catheter and lock solution technologies are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising chronic kidney disease prevalence and expanding dialysis centre infrastructure. China's rapidly expanding dialysis patient population leaves considerably more room for growth than in the already catheter-saturated North American market.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. B. Braun, headquartered in Germany, maintains a significant European hemodialysis catheter manufacturing and commercial presence. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding dialysis centre infrastructure driving early catheter demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised polyurethane and silicone catheter materials that Latin American device distributors depend on, an effect expected to run through 2026 and slow hemodialysis catheter adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding dialysis centre network and the UAE's regional distribution hubs represent the primary investment centres for hemodialysis catheter adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the dialysis infrastructure needed to support advanced catheter technologies at scale.